Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-121/tezacaftor/deutivacaftor in cystic fibrosis with responsive CFTR mutations
2021-000694-85Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started Sep 2021; status: completed.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2021-000694-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000694-85.